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Ethanol, as other drugs of abuse, is able to activate the ventral tegmental area dopamine
(VTA-DA) neurons leading to positively motivational alcohol-seeking behavior and use,
and, ultimately to ethanol addiction. In the last decades, the involvement of brain-derived
acetaldehyde (ACD) in the ethanol actions in the mesolimbic pathway has been widely
demonstrated. Consistent published results have provided a mechanistic support to
the use of ACD inactivating agents to block the motivational and reinforcing properties
of ethanol. Hence, in the last years, several pre-clinical studies have been performed
in order to analyze the effects of the sequestering ACD agents in the prevention
of ethanol relapse-like drinking behavior as well as in chronic alcohol consumption.
In this sense, one of the most explored interventions has been the administration
of D-Penicillamine (DP). These pre-clinical studies, that we critically summarize in
this article, are considered a critical step for the potential development of a novel
pharmacotherapeutic strategy for alcohol addiction treatment that could improve the
outcomes of current ones. Thus, on one hand, several experimental findings provide the
rationale for using DP as a novel therapeutic intervention alone and/or in combination
to prevent relapse into alcohol seeking and consumption. On the other hand, its
effectiveness in reducing voluntary ethanol consumption in long-term experienced
animals still remains unclear. Finally, this drug offers the additional advantage that has
already been approved for use in humans, hence it could be easily implemented as a
new therapeutic intervention for relapse prevention in alcoholism.
Keywords: D-penicillamine, pre-clinical studies, acetaldehyde sequestering agent, ethanol relapse prevention,
voluntary alcohol consumption
INTRODUCTION
In the last years, numerous studies have supported the idea that, at least in part, motivational
and neuropharmacological effects of ethanol are mediated by its first brain-derived
metabolite, acetaldehyde (ACD) and/or its bioderivates (for extensive review, see Deehan
et al., 2013; Peana et al., 2016). The most widely employed strategy to demonstrate the
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involvement of ACD in the motivational and reinforcing
effects of ethanol has been, for years, the pharmacological
manipulation of the enzyme system activity implicated in
the brain metabolism of this drug. For instance, modulating
catalase (Correa et al., 1999, 2004; Sanchis-Segura et al., 1999a,b;
Arizzi-LaFrance et al., 2006; Font et al., 2008), cytocrome
P-4502E1 (Hipolito et al., 2009; Ledesma et al., 2014) or
alcohol dehydrogenase (Escarabajal and Aragon, 2002) brain
activity.
Furthermore, another strategy has allowed disentangling
the role of ACD in different behavioral effects induced by
ethanol: the use of ACD sequestering agents. Fortunately, ACD
is a highly reactive molecule and, therefore, capable of being
‘‘sequestered’’ by thiol amino acids such as L-cysteine (L-cys) and
D-penicillamine (DP), which react non-enzymatically with ACD
to form stable non-toxic adducts. This fact has been evidenced
not only in vitro (Nagasawa et al., 1980; Kera et al., 1985)
but also in vivo (Serrano et al., 2007) experimental conditions.
Interestingly, these compounds, besides being used in the
aforementioned research strategy, could have other advantages,
particularly from a clinical point of view. In this sense, these
ACD-scavenging compounds would not alter neurotransmitter
systems, thus avoiding the manifestation of unexpected side
effects displayed by the most promising candidates which have
been evaluated in pre-clinical studies (Salaspuro et al., 2006;
Leggio et al., 2010). They act removing/blocking both hepatic and
brain-derived ACD, thus potentially preventing the reinforcing
and motivational properties of ethanol-derived ACD on specific
regions and pathways of the brain. Behavioral studies have
demonstrated that DP is able to: (i) dose-dependently prevent
the ethanol- and ACD-induced conditioned place preference
(CPP) in rodents (Font et al., 2006a,b; Peana et al., 2008,
2009); (ii) attenuate either behavioral depression caused by ACD
or behavioral locomotion induced by ethanol in mice (Font
et al., 2005); and (iii) prevent, in a dose-dependent manner,
the motor activation induced by intra-ventral tegmental area
(VTA) ethanol administration (Martí-Prats et al., 2010, 2013).
Additionally, neurochemical studies have evidenced that this
drug suppresses both ethanol- and ACD-induced stimulation
of dopamine (DA) release in the nucleus accumbens shell
as well as the ethanol-evoked excitation of VTA-DA neuron
activity (Enrico et al., 2009). Moreover, in most of these
articles, the specificity of DP effects has been addressed
using other drugs of abuse such as cocaine, caffeine or
morphine.
Considering these promising results, several groups have
explored the pre-clinical validity of ACD inactivation with
DP as an alternative strategy for the development of new
pharmacological approaches for treatment of alcoholism. Hence,
the effect of DP in the prevention of ethanol relapse-like drinking
behavior as well as in voluntary alcohol consumption have
been repeatedly demonstrated (Font et al., 2006b; Orrico et al.,
2013; Martí-Prats et al., 2015). In addition, the fact that DP is
currently approved by the Food and Drug Administration (FDA)
and European Medicines Agency (EMA) for other indications,
offers the additional advantage to its immediate potential clinical
utility.
In this review article, readers will find a compilation of the
most remarkable publications in which the potential use of DP in
the prevention of ethanol relapse-like drinking behavior as well
as in voluntary alcohol consumption has been investigated in a
pre-clinical environment.
Effect of DP in Relapse-Like Drinking
Behavior
Among the few animal models of relapse presently available,
the Alcohol Deprivation Effect (ADE—a marked increase in
ethanol consumption that follows periods of deprivation) has
become a widely used model to examine the efficacy of potential
medication providing excellent face and predictive validity (Rodd
et al., 2004; Spanagel and Kiefer, 2008; Spanagel, 2009; Bell
et al., 2012). For instance, the three medications currently
used in the clinical setting—Acamprosate, Naltrexone (NTX)
and Nalmefene—, although they have different pharmacological
mechanisms of action, have all been proven to effectively reduce
the ADE in rodents (Spanagel and Zieglgänsberger, 1997; Orrico
et al., 2014; Spanagel et al., 2014; Vengeliene et al., 2014).
Nowadays, Acamprosate’s primary mechanism of action still
remains unclear, although it is believed to normalize the balance
between excitatory and inhibitory pathways throughout the
glutamatercic system (De Witte et al., 2005). On the other hand,
NTX as well as Nalmefene work as opioid antagonists at µ and
δ receptors and as agonists at κ receptors (Wackernah et al.,
2014).
The ADE phenomenon can be triggered under both operant
(Hölter et al., 1997; Echeverry-Alzate et al., 2012) and home-cage
free choice drinking, non-operant, conditions (Spanagel and
Hölter, 1999; Vengeliene et al., 2014). In this sense, along the
last years, our group has extensively employed this latter model
to explore, for the first time, the potential role of DP in ethanol
relapse prevention.
Non-Operant Procedures
Our recent work has successfully shown that DP is able to
prevent the ADE in Wistar rats using a home-cage four-bottle
free choice (water, ethanol 5%, 10% and 20%) paradigm
(Orrico et al., 2013, 2014). Concretely, at the end of the
fifth deprivation period and 48 h before the reintroduction
of ethanol bottles, rats were subcutaneously (SC) implanted
with a mini-osmotic pump delivering at a constant rate either
vehicle or DP (1 or 0.25 mg/h), during 1 week. The results
obtained demonstrated that DP dose-dependently prevented
the ADE in long-term ethanol-experienced rats. In fact, the
constant-rate SC infusion of DP at a dose of 1 mg/h, but
not 0.25 mg/h, completely prevented the ADE phenomenon
(Figure 1A), while the vehicle-treated group increased the
ethanol intake along the four post-abstinence days compared
to baseline. Hence, our data clearly indicate that systemic
administration of DP is able to prevent the expression of the
ADE without affecting total fluid consumption and body weight
(Orrico et al., 2013).
In spite of these results, one important concern should
be considered. As can be seen in detail in the following
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FIGURE 1 | Effect of D-penicillamine (DP) on alcohol deprivation effect (ADE) measurements under both non-operant (A–C) and operant paradigms (D).
(A) Subcutaneous DP treatment dose-dependently suppresses the ADE manifestation. Effect of subcutaneous infusion of vehicle or DP (0.25 or 1 mg/h) on ethanol
intake. (B) Intra-ventral tegmental area (VTA) infusion of DP blocked the ADE expression. Effect of the intra-VTA infusion of vehicle or DP 3.0 µg/h on ethanol intake.
(C) DP prevents the “delayed ADE” induced by the continuous blockade of the opioid receptor with Naltrexone (NTX). Effect of vehicle, NTX or NTX/DP
administration on ethanol intake. In panels (A–C), animals had 9–11 months of ethanol experience. The percentage of each rat’s total daily ethanol intake during
post-abstinence drinking days was calculated with respect to baseline drinking just before deprivation (dashed line). The basal alcohol intake was about
0.6–1 g/kg/day. The deprivation period lasted 14 days. The assayed treatments began 48 h before the reintroduction of ethanol bottles (available 24 h along the
post-abstinence period). (D) DP is able to prevent the ADE under an operant paradigm. Average ethanol responses in animals intraperitoneally (i.p.) administrated
with saline (DP 0) or DP (6.25, 12.5 and 25 mg/kg), 30 min before each self-administration session in the post-abstinence period. Asterisk denotes statistically
significant differences relative to the respective baseline period (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001). Post hoc test showed differences between
groups (#p < 0.05, ##p < 0.01, ####p < 0.0001; Adapted from Orrico et al., 2013, 2014; Martí-Prats et al., 2015).
section, some studies have demonstrated that systemic, but
not intracerebroventricular (ICV), administration of DP is
able to produce changes in the taste of fluid and food
(Font et al., 2006a). Hence, the possibility that, at least,
part of the preventive effects of DP on the ADE could
be produced by an alteration in taste perception cannot be
fully ruled out. Nonetheless, and in agreement with these
results, our group also demonstrated that intra-posterior VTA
(pVTA) administration of DP was able to suppress the ADE
(Figure 1B), suggesting that the preventive effects of DP
on ADE could, at least in part, be caused specifically by
a mechanism independent of taste alteration (Orrico et al.,
2013).
Most drugs of abuse, including ethanol, stimulate the release
of DA in several limbic regions (Di Chiara, 2002). In recent years,
it has been shown that ACD is a crucial component of the overall
effects of ethanol on DA neurons of the VTA (Rodd-Henricks
et al., 2002; Rodd et al., 2005, 2008; Melis et al., 2007; Deehan
et al., 2013). Therefore, our results also showed, for the first
time, that pVTA is a critical region for DP action in relapse-like
drinking behavior and emphasize the role displayed by this brain
area in the relapse phenomenon.
The abovementioned results encouraged us to further study
the potential use of DP alone or in combination with other
marketed drugs (such as NTX) as a promising strategy to increase
the efficacy of current anti-relapse therapies, based on the
neurochemical studies that have confirmed that the mechanism
through which ethanol, or more probably ACD, excite DA
neurons is dependent on the Mu-Opioid Receptors (MORs;
Sánchez-Catalán et al., 2009; Peana et al., 2011). Accordingly,
our group next conjectured that the NTX/DP combination,
due to its distinct but complementary mechanisms of action
to impede MORs activation could be more efficacious in
ADE prevention (Orrico et al., 2014). Specifically, we explored
whether the combination of DP with NTX could suppress
the delayed ADE, i.e., the rebound in alcohol consumption
detected in animal laboratory models after continuous blockade
of the opioid receptor with antagonists such as NTX (Heyser
et al., 2003) or naloxone (Hölter and Spanagel, 1999).
In this sense, in several strains of rats using free choice
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paradigms it has been demonstrated that NTX decreases ethanol
consumption (Overstreet et al., 2006), however, tolerance to
this effect was demonstrated after repeated drug administration,
leading to an increase in alcohol consumption (Cowen et al.,
1999; Juárez and Eliana, 2007). This fact is probably due
to the MORs up-regulation associated with its continuous
blockade (Hyytiä et al., 1999; Overstreet et al., 1999; Orrico
et al., 2014). Thus, as can be seen in Figure 1C, in our
experimental conditions, NTX powerfully blocked the ADE on
post-abstinence days 1 and 2 in agreement with previously
published data, but an increase in alcohol consumption,
with respect to basal values, was detected on post-abstinence
days 3 and 4 (the manifestation of the so-called ‘‘delayed
ADE’’). The results obtained supported the efficacy of the
NTX/DP combination preventing not only the ADE expression,
but also the delayed ADE. In fact, the combination of DP
(0.25 mg/h; a non-effective dose in our previous article)
and NTX (2 × 5 mg/kg SC per day) showed an adequate
anti-relapse pre-clinical efficacy along the four post-abstinence
days.
In summary, the reported data demonstrate that
this therapeutic strategy, of combining two drugs with
complementary actions—opioid receptor blockade (by NTX)
and chemical ACD inactivation (by DP), shows adequate
alcohol anti-relapse-like drinking efficacy in long-term ethanol-
experienced rats. Moreover, it overcomes some therapeutic
limitations of either drug alone, since this combination
is able to block not only the delayed increase in ethanol
consumption, typically occurring after chronic opioid antagonist
administration, but it also allows the administration of
sub-threshold DP doses. All in all, these findings suggest that
sequestering agents of ACD, in general, and DP, in particular,
may represent a valuable therapy in the management of relapse
in alcohol-dependent patients.
Operant-Procedures
There is no doubt among researchers that in order to maximize
the translational power of pre-clinical research, it is important
to gather evidence for as many paradigms and different animal
models as possible (Bell et al., 2012). Hence, the use of different
paradigms to test the same observations would assure the
reproducibility of pre-clinical data, which is a challenge for
neuroscience (Steckler, 2015).
In this context, we were able to validate our previous
work on the pre-clinical efficacy of DP using a different
laboratory paradigm: an operant procedure. Several authors
have used this operant paradigm to demonstrate the capacity
of a number of drugs to reduce the expression of an operant
ADE (Schroeder et al., 2005; Rodd et al., 2006; Dhaher
et al., 2010). The results of our study showed that all DP
doses tested (6.25, 12.5, or 25 mg/kg), intraperitoneally (i.p.)
administered, were able to prevent the ADE in Wistar rats
using an operant fixed ratio (FR) 1 procedure (Figure 1D).
Contrarily to the saline group (named ‘‘DP 0’’), DP blocked
the increase in ethanol response following the imposed period
of abstinence. Interestingly, animals treated with the higher
DP dose (25 mg/kg) even reduced their response to ethanol
significantly, by 20% below baseline levels. Moreover, DP
did not modify the spontaneous motor activity of the rats
indicating that the effectiveness of DP in preventing ADE cannot
be due to a reduced locomotor performance of the animals
(Martí-Prats et al., 2015). These results added reproducibility
and robustness to previously reported data. Hence, to sum
up, we were able to replicate our previous outcomes in a
different laboratory (Laboratory of Psychobiology, Complutense
University of Madrid) and using a different paradigm, (inter-
lab reliability) leading to more robust conclusions on the use
of DP as a potential new pharmacotherapy in the treatment of
alcoholism.
Effect of DP on Voluntary Ethanol
Consumption Behavior
As illustrated above, findings of different research groups
working in the field agree with the efficacy of DP as a
valid strategy to prevent alcohol relapse-like drinking behavior,
denoting the relevant role of ACD on the relapse expression.
Conversely, concerning voluntary ethanol intake, the few
published studies reveal contradictory results on the efficacy of
DP (Font et al., 2006b; Campos-Jurado et al., 2015; Gosalbez
et al., 2015).
Font et al. (2006b) were the first group to evaluate the
effect of DP on voluntary ethanol consumption. In their study,
male Long-Evans rats had daily access to a 10% ethanol
solution in their home-cages for a 15-min period. Under their
experimental conditions, the systemic (50 and 75 mg/kg), as
well as ICV (75 µg) administration of DP was able to decrease
the ethanol intake during the 5-day treatment. Interestingly,
after discontinuation of the treatment, animals recovered their
previous consumption rates. These results represent the initial
evidence of ACD sequestration usefulness as a possible valid
strategy to prevent ethanol drinking. However, in the same study,
the authors also showed that systemic, but not ICV, DP treatment
modified sucrose intake. According to the taste reactivity test
performed, authors attributed this effect to a modification of
ethanol palatability due to DP administration. Thus, all these
results suggest that, although part of the DP effect on modulating
ethanol consumption could be ascribed to a taste modification,
an effect on the central levels of ACD has also been demonstrated
(Font et al., 2006b).
Since the abovementioned study, it was not until nearly
10 years later that new research evaluating the utility of DP
on the voluntary ethanol intake was performed. Concretely,
Peana et al. (2015) studied the validity of DP on the acquisition
and maintenance of oral operant ethanol self-administration.
For acquisition analysis, ethanol-naïve Wistar rats were i.p.
administered with DP (50 mg/kg) concomitant with the access
to ethanol solution under an FR-1 schedule of reinforcement.
The ethanol concentration was gradually increased from 5%
in the first three sessions to 10% in the eighth last session.
In this phase, systemic DP treatment significantly reduced the
number of ethanol nose pokes, consistent with an ethanol intake
decrease from the second ethanol session until the end of
the study. Nevertheless, when rats, after an acquisition period,
self-administered 10% ethanol for at least 10 days, the same
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DP treatment (50 m/kg) failed to reduce active nose pokes for
ethanol. Indeed, the double dose of DP (100 mg/kg) was also
unable to diminish ethanol self-administration. Furthermore,
DP 50 mg/kg did not diminish the ethanol intake when the
solution was changed from 10% to 5%, neither alone nor in
combination with the catalase inhibitor amino-1,2,4-triazole
(1 g/kg). Curiously, this catalase inhibitor, that has shown
to be effective in reducing ethanol consumption during the
acquisition phase, was ineffective along the maintenance phase
(Peana et al., 2015). Hence, these results confirm the DP efficacy
in impairing the acquisition of ethanol self-administration
in naïve animals, but not in reducing active responses in
ethanol-experienced animals. Indeed, ethanol-experienced rats
increased their nose pokes when the ethanol concentration was
reduced from 10% to 5% in order to obtain the same ethanol
intake. According to these authors, a possible explanation for
the failure of DP activity could be that ACD, paradoxically
contributes to the perpetuation of ethanol self-administration,
concretely the reduction of ACD levels due to the administered
treatment might motivate rats to further seek and take ethanol
to compensate for that decrease. Moreover, according to
the abovementioned authors, additional explanations could
be plausible since in these experimental conditions, due to
its mechanism of action, DP would allow the increase of
the non-metabolized fraction of ethanol in relation to the
metabolized fraction (ACD and its derivatives). Under this
condition, some studies have reported that ethanol, through the
GABAA receptor, might lead to different behavioral responses
such as decreasing the rat’s locomotor activity (Martí-Prats
et al., 2015) or increasing the responses in the paradigm of
alcohol self-administration (Kumar et al., 2009; Kaminski et al.,
2013).
Finally, two additional pre-clinical studies have recently
evaluated the ability of DP to prevent voluntary ethanol
consumption, in both ethanol-naïve and ethanol-experienced
Wistar rats, in their home-cages and under non-operant
procedures (Campos-Jurado et al., 2015; Gosalbez et al., 2015).
In the former, animals were SC implanted with a mini-osmotic
pump delivering either vehicle or DP 1 mg/h along a 1-week
period. One day after surgery, every animal was exposed in
its home-cage, for the first time, to a four-bottle alcohol
self-administration model. Along the next 6 days of treatment,
although DP did not modify the voluntary ethanol intake, a
significant reduction in the preference for ethanol, with respect
to total volume of consumed liquid, was detected in the animals
receiving DP. No statistical differences were detected in the
next 6 days after treatment (post-treatment phase) between both
experimental groups (Figures 2A,B).
With regard to the ethanol-experienced rats, animals were
exposed to ethanol, under a non-operant paradigm during
a 14-week period. Next, ethanol intake was registered on a
daily basis along 3 weeks, each week corresponding to a
different experimental period: (i) Pre-treatment: baseline intake
was established; (ii) Treatment: a mini-osmotic pump was
implanted in animals delivering DP 1 mg/h along 1 week;
(iii) Post-treatment: the mini-osmotic pump was removed.
Thereafter, rats continued to drink freely for 2 weeks before
repeating the same experimental procedure, although pumps
delivered sterilized water (vehicle) instead of DP. In this
study, no differences in ethanol consumption nor ethanol
preference were reported when animals received 1 mg/h
DP treatment (Figures 2C,D). Nevertheless, after DP was
administered (post-treatment phase), rats increased their ethanol
preference in relation to pre-treatment and treatment phases,
however, ethanol intake remained unmodified. Yet, these
data suggest that, at the tested DP dose, a change in the
consumption pattern takes place, without altering the total
ethanol consumption.
Although different studies denote the existence of a positive
correlation between brain ACD levels and alcohol intake (Correa
et al., 2012; Muggironi et al., 2013; Israel et al., 2015), some
aspects still remain unclear. In this sense, the inhibition of the
brain ACD formation has been related to a reduction in the
voluntary ethanol intake in mice and rats (Aragon and Amit,
1985, 1992; Koechling and Amit, 1994; Karahanian et al., 2011;
Quintanilla et al., 2012; Ledesma et al., 2014). Moreover, the
increase of the ACD metabolism (Karahanian et al., 2015) or
the reduction of ACD disposition (Font et al., 2006b; Peana
et al., 2010) has also been associated with a significant inhibition
of voluntary ethanol consumption. Conversely, and consistent
with some of the results exposed herein, different groups have
reported that several strategies aimed at reducing the ACD
levels in the brain, inhibition of its formation (Quintanilla
et al., 2012; Tampier et al., 2013; Karahanian et al., 2015;
Peana et al., 2015) or, as shown before, ACD inactivation
(Campos-Jurado et al., 2015; Gosalbez et al., 2015), have not
been able to impair the ethanol intake when experimental
animals have moderate to long ethanol-experience. Recently,
some studies have suggested a differential influence of ACD
on the ethanol intake. It has been proposed that the key role
of ACD in the ethanol reinforcing properties could be limited
to the initial ethanol experience (called first hit), while after
this first phase, ethanol consumption may not depend on ACD
levels (Israel et al., 2015; Quintanilla et al., 2016). However,
alternative explanations in relation with divergent results have
also been taken into account. On the one hand, some of the
studies supporting the preceding theory (Quintanilla et al., 2012;
Karahanian et al., 2015) have focused on the manipulation of
ACD levels only in the VTA, leaving open the possibility that
other brain areas could be involved in the maintenance of alcohol
intake (Karahanian et al., 2015). On the other hand, ethanol-
related cues could also support the perpetuation of ethanol
drinking behavior independent of its reinforcing properties
(Greeley et al., 1993; Miller and Gold, 1994; O’Brien et al.,
1998; Tiffany and Carter, 1998; Everitt et al., 2001; Littleton
et al., 2001; See, 2002; Ingjaldsson et al., 2003a,b; van de Laar
et al., 2004; Weiss, 2010; Karahanian et al., 2015; Peana et al.,
2015).
Taking all the data into consideration, several of the
hypotheses exposed could be due to the different data obtained.
However, the diversity of protocols, experimental animals,
rodent strains and duration of ethanol expositionmake it difficult
to realistically compare the results obtained in the published
studies hitherto. Hence, further studies are required to obtain a
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FIGURE 2 | Effect of systemic administration of DP on voluntary ethanol intake and alcohol preference in ethanol-naïve (A,B) or in long-term
ethanol-experienced rats (C,D). (A) DP does not modify voluntary ethanol intake in ethanol-naïve rats (B) DP reduced ethanol preference in ethanol-naïve rats. In
panels (A,B), animals received DP (1 mg/h) or vehicle, from a mini-osmotic pump subcutaneously (SC) implanted, along the treatment phase. Along the
post-treatment phase no substance was administered. Asterisk denotes statistically significant differences with regard to the vehicle group (p < 0.05). (C) DP does
not modify voluntary ethanol intake in long-term ethanol experienced rats. (D) DP does not modify ethanol preference in long-term ethanol experienced rats. A
change in ethanol preference was detected after DP treatment only. In panels (C,D), animals received DP (1 mg/h) or vehicle, from a mini-osmotic pump SC
implanted, only along the treatment phase. Along the pre-treatment and post-treatment phase no substance was administered. Asterisk denotes statistically
significant differences relative to the pre-treatment and treatment phases (∗p < 0.05; Adapted from Campos-Jurado et al., 2015; Gosalbez et al., 2015).
firmer conclusion about DP efficacy in relation with voluntary
ethanol intake.
CONCLUSIVE REMARKS AND FUTURE
DIRECTIONS
To sum up, all of these experimental findings provide the
rationale for using ACD sequestering agents, concretely DP, as
a novel therapeutic intervention alone and or in combination
to prevent relapse into alcohol seeking and consumption. In
fact, there is a consensus among researchers that this potential
therapeutic avenue deserves more attention and investigation
(Melis et al., 2007; Sanchis and Aragón, 2007; Enrico et al., 2009;
Peana et al., 2010; Orrico et al., 2013, 2014). This is also based
on the fact that this drug acts as an ACD-scavenging compound
(Nagasawa et al., 1980) without altering any neurotransmitter
systems (Salaspuro et al., 2006). Hence, we hypothesized that
DP could be a promising drug for preventing alcohol relapse.
On the other hand, its effectiveness in reducing voluntary
ethanol consumption in long-term experienced patients still
remains unclear. In this sense, in our opinion, one possibility
that could be clinically explored is its administration ‘‘as
needed’’ in agreement with the latest trends in therapy such
as with Nalmefene. Additionally, another point in favor of
this strategy is the fact that DP has already been approved
for its use in humans, hence, this fact would lead to a faster
and easier way of inclusion in the present limited therapeutic
arsenal. In conclusion, there is a vast amount of pre-clinical
research that demonstrates the potential use of DP for treating
alcoholism. At this point, it is time for clinical researchers to
try to cross the so-called ‘‘Valley of Death’’ for alcohol drug
development, i.e., the gap between the demonstrated efficacy
in pre-clinical animal models and clinical testing. This gap
has impeded several promising novel compounds from moving
forward along the drug development pipeline (Litten et al.,
2012).
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